WallStreetZenWallStreetZen

NASDAQ: HIT
Health In Tech Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for HIT

Based on 1 analyst offering 12 month price targets for Health In Tech Inc

Min Forecast
$3.00+390.2%
Avg Forecast
$3.00+390.2%
Max Forecast
$3.00+390.2%

Should I buy or sell HIT stock?

Based on 1 analyst offering ratings for Health In Tech Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HIT stock forecasts and price targets.

HIT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-14

1 of 1

Forecast return on equity

Is HIT forecast to generate an efficient return?

Company
-14.68%
Industry
46.73%
Market
137.8%
HIT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HIT forecast to generate an efficient return on assets?

Company
-9.69%
Industry
27.6%
HIT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HIT earnings per share forecast

What is HIT's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.21
Avg 2 year Forecast
-$0.04

HIT revenue forecast

What is HIT's revenue in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$35.2M+7.25%
Avg 2 year Forecast
$54.6M+66.22%
HIT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HIT revenue growth forecast

How is HIT forecast to perform vs Software - Application companies and vs the US market?

Company
7.25%
Industry
15.57%
Market
19.93%
HIT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HIT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HIT vs App Stocks

TickerPricePrice TargetUp/downsideConsensus
HIT$0.61$3.00+390.20%Strong Buy
SWVL$4.11N/AN/A
PHUN$1.86N/AN/A
XTIA$1.11$2.00+80.18%Strong Buy
IDN$2.32$5.00+115.98%Strong Buy
View Top App Stocks

Health In Tech Stock Forecast FAQ

Is Health In Tech Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: HIT) stock is to Strong Buy HIT stock.

Out of 1 analyst, 1 (100%) are recommending HIT as a Strong Buy, 0 (0%) are recommending HIT as a Buy, 0 (0%) are recommending HIT as a Hold, 0 (0%) are recommending HIT as a Sell, and 0 (0%) are recommending HIT as a Strong Sell.

If you're new to stock investing, here's how to buy Health In Tech stock.

What is HIT's earnings growth forecast for 2026-2027?

(NASDAQ: HIT) Health In Tech's forecast annual earnings growth rate of N/A is not forecast to beat the US Software - Application industry's average forecast earnings growth rate of 75.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,302.87%.

Health In Tech's earnings in 2026 is -$3,949,686.On average, 4 Wall Street analysts forecast HIT's earnings for 2026 to be -$13,899,901, with the lowest HIT earnings forecast at -$19,909,429, and the highest HIT earnings forecast at -$8,257,367.

In 2027, HIT is forecast to generate -$2,870,418 in earnings, with the lowest earnings forecast at -$16,698,231 and the highest earnings forecast at $6,881,139.

What is HIT's revenue growth forecast for 2026-2027?

(NASDAQ: HIT) Health In Tech's forecast annual revenue growth rate of 7.25% is not forecast to beat the US Software - Application industry's average forecast revenue growth rate of 15.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 19.93%.

Health In Tech's revenue in 2026 is $32,826,944.On average, 4 Wall Street analysts forecast HIT's revenue for 2026 to be $2,307,278,704, with the lowest HIT revenue forecast at $1,967,022,760, and the highest HIT revenue forecast at $2,820,677,215.

In 2027, HIT is forecast to generate $3,575,833,079 in revenue, with the lowest revenue forecast at $2,180,862,349 and the highest revenue forecast at $5,348,217,905.

What is HIT's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: HIT) forecast ROA is -9.69%, which is lower than the forecast US Software - Application industry average of 27.6%.

What is HIT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year HIT price target, the average HIT price target is $3.00, with the highest HIT stock price forecast at $3.00 and the lowest HIT stock price forecast at $3.00.

The Wall Street analyst predicted that Health In Tech's share price could reach $3.00 by Aug 14, 2027. The average Health In Tech stock price prediction forecasts a potential upside of 390.2% from the current HIT share price of $0.61.

What is HIT's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: HIT) Health In Tech's current Earnings Per Share (EPS) is -$0.07. On average, analysts forecast that HIT's EPS will be -$0.21 for 2026, with the lowest EPS forecast at -$0.30, and the highest EPS forecast at -$0.13. In 2027, HIT's EPS is forecast to hit -$0.04 (min: -$0.25, max: $0.11).

What is HIT's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: HIT) forecast ROE is -14.68%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.